Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900
Debt
Debt-to-Equity RatioN/A
Current Ratio1.94
Quick Ratio1.94
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-6.11
Profitability
EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-658.91%
Return on Assets-140.82%
Miscellaneous
Employees45
Outstanding Shares28,690,000
Histogenics (NASDAQ:HSGX) Frequently Asked Questions
What is Histogenics' stock symbol?
Histogenics trades on the NASDAQ under the ticker symbol "HSGX."
How were Histogenics' earnings last quarter?
Histogenics Corp (NASDAQ:HSGX) released its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.45. View Histogenics' Earnings History.
When is Histogenics' next earnings date?
What price target have analysts set for HSGX?
2 analysts have issued twelve-month price objectives for Histogenics' stock. Their predictions range from $4.00 to $4.00. On average, they expect Histogenics' stock price to reach $4.00 in the next year. View Analyst Ratings for Histogenics.
Who are some of Histogenics' key competitors?
Who are Histogenics' key executives?
Histogenics' management team includes the folowing people:
- Mr. Adam D. Gridley, Pres, CEO & Director (Age 46)
- Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
- Mr. Stephen R. Kennedy, Exec. VP & COO (Age 61)
- Dr. Donald D. Haut, Chief Bus. Officer (Age 52)
- Mr. Peter Hamilton, VP of Operations & Engineering (Age 54)
When did Histogenics IPO?
(HSGX) raised $60 million in an initial public offering (IPO) on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.
Has Histogenics been receiving favorable news coverage?
Headlines about HSGX stock have trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Histogenics earned a news sentiment score of 0.20 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.42 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Histogenics' major shareholders?
Histogenics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sofinnova Ventures Inc (7.24%), Archon Capital Management LLC (0.81%), JPMorgan Chase & Co. (0.41%) and Bradley Foster & Sargent Inc. CT (0.25%). Company insiders that own Histogenics stock include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Institutional Ownership Trends for Histogenics.
Which institutional investors are buying Histogenics stock?
HSGX stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Archon Capital Management LLC, JPMorgan Chase & Co. and Bradley Foster & Sargent Inc. CT. Company insiders that have bought Histogenics stock in the last two years include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp. View Insider Buying and Selling for Histogenics.
How do I buy shares of Histogenics?
Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Histogenics' stock price today?
One share of HSGX stock can currently be purchased for approximately $2.81.
How big of a company is Histogenics?
Histogenics has a market capitalization of $82.91 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.
How can I contact Histogenics?
Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]
MarketBeat Community Rating for Histogenics (HSGX)
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
